Immunotherapy can fire up a protein that disables a T cell attack
Lung cancer immunotherapy triggers a counterattack by a surface protein found on the tumors of some patients that stifles the immune system's assault, researchers at MD Anderson Cancer Center report in Cancer Discovery.
Their research shows in detail how the protein, called CD38, reaches out to disable attacking immune system T cells and points to a variety of drugs that could counter CD38's defenses. One such...
Collaboration yields comprehensive CAR T-cell therapy pediatric guidelines
Almost one year after the Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children with...
MD Anderson once again named No. 1 for cancer care
MD Anderson Cancer Center again has been ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best Hospitals” survey...
Communication skills may help keep research trainees on the academic track
A well-trained research workforce is essential for addressing both current and future health challenges in the U.S. However, according to a 2012 report from the National Institutes of Health (NIH) Biomedical Research Workforce Working Group, the proportion of biomedical and behavioral research trainees that progress to established academic research positions is declining.
In 1993, 34 percent of all Ph.D. students went on to...
New venture will lead to new treatments for chemotherapy's side effects
MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and management firm, have launched Magnolia...
Uncovering an enemy of lung cancer immunotherapy
MD Anderson researchers have uncovered a genetic condition that thwarts the most common immunotherapy used against lung cancer, opening new...